Clinical trial · Observational
Multicentric Cohort of Melanoma Patients in Ile de France Area
NCT00839410CI-TRIAL-00041001Melan-CohortcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicentric prospective cohort of all stage melanoma patients from AP-HP ,the largest consortium of University hospitals over Europe. 7 investigation sites (7 dermatological services of AP-HP) in Ile de France region are involved. 1300 patients will be enrolled and be followed during 10 years.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Polymorphism | — | UNRESOLVED | — |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (0-10 years) Disease free survival (0-10 years)
- timeFrame
- 10 years
Secondary outcomes (1)
- measure
- Invasion of sentinel lymph node biopsy
- timeFrame
- 2003-2009
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : * age ≥ 18 years * an informed consent is obtained * patients with anatomy-pathologically proved melanoma * the tissue sample of melanoma is available * the primary melanoma is treated according to the international standard * absence of a progressive non neoplastic pathology involving life-threatening * patient living in Ile de France region. * time limit to entry in the cohort must be: * within 3 months after Surgical resumption of primary melanoma; * within 3 months after curative surgical treatment; * with one month after diagnosis of a transit metastasis or a distant metastasis. Exclusion criteria : * refusal of the patient * pathology sample isn't available * primary melanoma not being treated according to the international standard * patient living too far to follow regular visits * patient diagnosed with a progressive non neoplastic pathology involving life-threatening * too late to entry and lack of useful stored specimens to research.
References
Publications (0)
Data not yet available
No reference posted for this study.